Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 1, 2002, Pages 46-52

  Munshi, A ^a   McDonnell, T ^a   Meyn, R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Chemotherapy; Clonogenic assay; DNA fragmentation; TRAIL

Indexed keywords

ANTIINFECTIVE AGENT; CASPASE; CISPLATIN; DNA FRAGMENT; DOXORUBICIN; ETOPOSIDE; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL KILLING; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CASPASES; CELL SURVIVAL; CISPLATIN; COMBINED MODALITY THERAPY; DOXORUBICIN; DRUG SYNERGISM; ETOPOSIDE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; TUMOR STEM CELL ASSAY;

EID: 0036307244     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0465-z     Document Type: Article

References (44)

1. Apoptosis control by death and decoy receptors
2. Bcl-2 inhibits p53 nuclear import following DNA damage
3. Bcl-2 expression correlates with apoptosis induction but not loss of clonogenic survival in small cell lung cancer cell lines treated with etoposide
4. The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo
5. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells
6. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan
7. Expression of bcl-2 in human epithelial tumor (HeLa) cells enhances clonogenic survival following exposure to 5-fluoro-2′-deoxyuridine or staurosporine, but not following exposure to etoposide or doxorubicin
8. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL
9. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11
10. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells
11. TRAIL: A molecule with multiple receptors and control mechanisms
12. Bcl-2 overexpression and activation of protein kinase C suppress the trail-induced apoptosis in Jurkat T cells
13. Sensitization of human colon cancer cells to TRAIL-mediated apoptosis
14. Bcl-2 suppresses apoptosis resulting from disruption of the NF-kB survival pathway
15. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
16. Bcl-xL overexpression inhibits Taxol induced Yama protease activity and apoptosis
17. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death
18. Programmed cell death and bcl-2 protection in the absence of a nucleus
19. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
20. Molecular determinants of response to TRAIL in killing of normal and cancer cells
21. Bcl-2 initiates a new category of oncogenes: Regulators of cell death
22. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis
23. Tumor necrosis factor-related apoptosis inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines
24. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells
25. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
26. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin
27. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by bcl-2
28. p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: An analysis of medically managed patients
29. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo
30. The potential of TRAIL for cancer chemotherapy
31. Cell free apoptosis in Xenopus egg extracts: Inhibition by bcl-2 and requirement for an organelle fraction enriched in mitochondria
32. Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis
33. Pretreatment with paclitaxel enhances Apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels
34. Bcl-2: Prevention of apoptosis as a mechanism of drug resistance
35. Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes
36. High levels of p26BCL-2 oncoprotein retard Taxol-induced apoptosis in human pre-B leukemia cells
37. Apoptosis in the pathogenesis and treatment of disease
38. The caspase family of cysteine proteases
39. Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells
40. Bcl-2 gene promotes hematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
41. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells
42. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines
43. Bcl-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells
44. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma